Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2010

01-10-2010 | Case Report

Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone

Authors: Daisuke Katagiri, Maki Shibata, Takashi Katsuki, Shoichi Masumoto, Ai Katsuma, Eri Minami, Taro Hoshino, Tsuyoshi Inoue, Manami Tada, Fumihiko Hinoshita

Published in: Clinical and Experimental Nephrology | Issue 5/2010

Login to get access

Abstract

An elderly patient with pure red cell aplasia (PRCA) with antierythropoietin (anti-EPO) antibodies is described. PRCA due to alloimmunization is a rare and severe complication of recombinant human erythropoietin (rHu-EPO) therapy. Most reported patients with PRCA were cured primarily by immunosuppressive drug therapy. The patient in this case, however, did not want to receive any immunosuppressive drugs. Therefore, rHu-EPO injection was simply discontinued, the severe anemia gradually improved, and the hemoglobin approached normal range. This case is very rare and significant in that there have been few such elderly patients with rHu-EPO-induced PRCA in whom PRCA remission was achieved, with decreasing antibody titers, after cessation of rHu-EPO alone. Further cases are needed to assess how PRCA should be treated in patients with anti-EPO antibodies.
Literature
1.
go back to reference Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.CrossRefPubMed Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.CrossRefPubMed
2.
go back to reference Shinohara K, Mitani N, Miyazaki M, Sakuragi S, Matsuda K, Ogawara S, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15–20.CrossRefPubMed Shinohara K, Mitani N, Miyazaki M, Sakuragi S, Matsuda K, Ogawara S, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15–20.CrossRefPubMed
3.
go back to reference Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.CrossRefPubMed Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol. 2002;13:2381–3.CrossRefPubMed
4.
go back to reference Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004;96:c88–95.CrossRefPubMed Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract. 2004;96:c88–95.CrossRefPubMed
5.
go back to reference Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest. 2005;35(Suppl 3):95–9.PubMed Rossert J. Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest. 2005;35(Suppl 3):95–9.PubMed
6.
go back to reference Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768–71.CrossRefPubMed Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768–71.CrossRefPubMed
7.
go back to reference Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343–7.CrossRefPubMed Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343–7.CrossRefPubMed
8.
9.
go back to reference Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed
10.
go back to reference Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891–8.CrossRefPubMed Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114:891–8.CrossRefPubMed
11.
go back to reference Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol. 1997;47:331–5.PubMed Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol. 1997;47:331–5.PubMed
12.
go back to reference Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–3.CrossRefPubMed Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med. 1996;334:630–3.CrossRefPubMed
13.
go back to reference Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transpl. 2008;23:2416–8.CrossRef Viron B, Dupuy CA, Kolta A, Casadevall N. Successful re-challenge with darbepoetin in a patient with rHu-EPO-induced pure red cell aplasia refractory to immunosuppressive drugs. Nephrol Dial Transpl. 2008;23:2416–8.CrossRef
14.
go back to reference Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.CrossRefPubMed Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108:1830–4.CrossRefPubMed
15.
go back to reference Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.CrossRefPubMed Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.CrossRefPubMed
Metadata
Title
Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone
Authors
Daisuke Katagiri
Maki Shibata
Takashi Katsuki
Shoichi Masumoto
Ai Katsuma
Eri Minami
Taro Hoshino
Tsuyoshi Inoue
Manami Tada
Fumihiko Hinoshita
Publication date
01-10-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0318-8

Other articles of this Issue 5/2010

Clinical and Experimental Nephrology 5/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.